IL17A and prostate cancer: The enrichment pathways identified following KEGG analysis that contained the most core targets included prostate cancer, endocrine resistance, proteoglycans in cancer, adherens junction, insulin resistance, the IL-17 signaling pathway, the PI3K-Akt signaling pathway, and others (Figure S5B).